C4 Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

C4 Therapeutics

01/11/2023 12:55

* C4 Therapeutics Inc  CCCC.OQ  reported a quarterly
adjusted loss
of 52 cents​​ per share for the quarter ended in September,
higher than the same quarter last year, when the company
reported EPS of -65 cents.  The mean expectation of
nine analysts for the quarter was for a loss of 66 cents per
share. Wall Street expected results to range from -83 cents
to -48 cents per share.
    * Revenue rose 63.9% to $11.07 million from a year ago;
analysts
expected $5.46 million. 
    * C4 Therapeutics Inc's reported EPS for the quarter was a
loss
of 55 cents​.
    * The company reported a quarterly loss of $27.04 million.
    * C4 Therapeutics Inc shares had fallen by 19.9% this
quarter and
lost 74.7% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 7.8%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 2
"hold" and 2 "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for C4 Therapeutics
Inc is $15.00 
This summary was machine generated from LSEG data November 1 at
12:55 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2023      -0.66          -0.52          Beat
 Jun. 30 2023      -0.69          -0.73          Missed
 Mar. 31 2023      -0.75          -0.71          Beat
 Dec. 31 2022      -0.74          -0.77          Missed